Table 1.

Patients characteristics

Variables
Number of patients (n)	43
Age (median [range])	61 (35–78)
Gender (# male [%])	19 (44.2%)
Stage (n [%])	IIIb: 4 (9.3%); IV: 39 (90.7%)
Demonstrable EGFR mutations (n [%])	5 (11.6%)
Disease stabilization at 12 weeks (n [%])	23 (53.5%)
Tumor shrinkage at 12 weeks (median [IQR]), in % of tumor size at baseline	15.8% (−2.5 to 26.2%)
Median overall survival (95% CI), in months	11.1 (10.1–17.9)
Median time-to-progression under BE (95% CI), in months	4.0 (2.8–6.0)
Median time-to-progression under CT (95% CI), in months	2.6 (1.7–5.7)

The table summarizes the characteristics of the 43 patients included in the study